162 related articles for article (PubMed ID: 16926289)
1. Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice.
Bobé P; Bonardelle D; Benihoud K; Opolon P; Chelbi-Alix MK
Blood; 2006 Dec; 108(13):3967-75. PubMed ID: 16926289
[TBL] [Abstract][Full Text] [Related]
2. [New therapeutic perspectives for arsenic: from acute promyelocytic leukemia to autoimmune diseases].
Bobé P; Chelbi-Alix MK
Med Sci (Paris); 2008 Nov; 24(11):967-71. PubMed ID: 19038100
[TBL] [Abstract][Full Text] [Related]
3. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.
Kitamura K; Minami Y; Yamamoto K; Akao Y; Kiyoi H; Saito H; Naoe T
Leukemia; 2000 Oct; 14(10):1743-50. PubMed ID: 11021749
[TBL] [Abstract][Full Text] [Related]
4. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
[TBL] [Abstract][Full Text] [Related]
5. Tetra-arsenic tetra-sulfide ameliorates lupus syndromes by inhibiting IL-17 producing double negative T cells.
Zhao Y; Mu Z; Cai L; Liu X; Jia J; Zhang J
Dermatol Ther; 2019 Jul; 32(4):e12849. PubMed ID: 30707471
[TBL] [Abstract][Full Text] [Related]
6. Abnormal thymic maturation and lymphoproliferation in MRL-Fas
Ashman RF; Singh N; Lenert PS
Lupus; 2017 Jun; 26(7):734-745. PubMed ID: 27837196
[TBL] [Abstract][Full Text] [Related]
7. Targeting Notch signaling in autoimmune and lymphoproliferative disease.
Teachey DT; Seif AE; Brown VI; Bruno M; Bunte RM; Chang YJ; Choi JK; Fish JD; Hall J; Reid GS; Ryan T; Sheen C; Zweidler-McKay P; Grupp SA
Blood; 2008 Jan; 111(2):705-14. PubMed ID: 17925488
[TBL] [Abstract][Full Text] [Related]
8. Deletion of receptor for advanced glycation end products exacerbates lymphoproliferative syndrome and lupus nephritis in B6-MRL Fas lpr/j mice.
Goury A; Meghraoui-Kheddar A; Belmokhtar K; Vuiblet V; Ortillon J; Jaisson S; Devy J; Le Naour R; Tabary T; Cohen JH; Schmidt AM; Rieu P; Touré F
J Immunol; 2015 Apr; 194(8):3612-22. PubMed ID: 25762779
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of leukemic T-cell lines to arsenic trioxide cytotoxicity is dependent on the induction of phosphatase B220/CD45R expression at the cell surface.
Benbijja M; Mellouk A; Bobé P
Mol Cancer; 2014 Nov; 13():251. PubMed ID: 25410152
[TBL] [Abstract][Full Text] [Related]
10. Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice.
Chesnutt MS; Finck BK; Killeen N; Connolly MK; Goodman H; Wofsy D
Clin Immunol Immunopathol; 1998 Apr; 87(1):23-32. PubMed ID: 9576007
[TBL] [Abstract][Full Text] [Related]
11. Effects of Arsenic Trioxide on INF-gamma Gene Expression in MRL/lpr Mice and Human Lupus.
Hu H; Chen E; Li Y; Zhu X; Zhang T; Zhu X
Biol Trace Elem Res; 2018 Aug; 184(2):391-397. PubMed ID: 29159556
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus.
Shimp SK; Chafin CB; Regna NL; Hammond SE; Read MA; Caudell DL; Rylander M; Reilly CM
Cell Mol Immunol; 2012 May; 9(3):255-66. PubMed ID: 22543833
[TBL] [Abstract][Full Text] [Related]
13. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS).
Dowdell KC; Pesnicak L; Hoffmann V; Steadman K; Remaley AT; Cohen JI; Straus SE; Rao VK
Exp Hematol; 2009 Apr; 37(4):487-94. PubMed ID: 19217201
[TBL] [Abstract][Full Text] [Related]
15. Terminal deoxynucleotidyl transferase deficiency decreases autoimmune disease in MRL-Fas(lpr) mice.
Feeney AJ; Lawson BR; Kono DH; Theofilopoulos AN
J Immunol; 2001 Sep; 167(6):3486-93. PubMed ID: 11544342
[TBL] [Abstract][Full Text] [Related]
16. Type I IFN protects against murine lupus.
Hron JD; Peng SL
J Immunol; 2004 Aug; 173(3):2134-42. PubMed ID: 15265950
[TBL] [Abstract][Full Text] [Related]
17. Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome.
Rao VK; Dowdell KC; Dale JK; Dugan F; Pesnicak L; Bi LL; Hoffmann V; Penzak S; Avila NA; Fleisher TA; Puck JM; Straus SE
Am J Hematol; 2007 Dec; 82(12):1049-55. PubMed ID: 17674358
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
Dang WZ; Li H; Jiang B; Nandakumar KS; Liu KF; Liu LX; Yu XC; Tan HJ; Zhou C
Phytomedicine; 2019 Sep; 62():152965. PubMed ID: 31129432
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation.
Ishitsuka K; Ikeda R; Utsunomiya A; Uozumi K; Hanada S; Suzuki S; Takeuchi S; Takatsuka Y; Takeshita T; Ohno N; Arima T
Leuk Lymphoma; 2002 May; 43(5):1107-14. PubMed ID: 12148893
[TBL] [Abstract][Full Text] [Related]
20. Characterization of reciprocal Lmb1-4 interval MRL-Faslpr and C57BL/6-Faslpr congenic mice reveals significant effects from Lmb3.
Santiago-Raber ML; Haraldsson MK; Theofilopoulos AN; Kono DH
J Immunol; 2007 Jun; 178(12):8195-202. PubMed ID: 17548658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
